In a $26.5-billion merger, Caremark and CVS will bring a new dynamic to the pharmacy industry. The combination will create one company that will be the nation's number- 2 drugstore chain and its largest pharmacy benefit management (PBM) company.
"This is what we've been working to get toto get the shareholders to vote on what we think is a game-changing event in the pharmaceutical industry," said Edwin Crawford, Caremark's chief executive officer, during a press conference following the merger vote.
Crawford said that he expects the formal integration process to take 6 months to a year.
CVS agreed. "We have said from the beginning that this combination will transform the way pharmacy services are delivered, enabling consumers to benefit from enhanced health care services and improved outcomes, and ...payers to benefit from more effective cost-management tools," commented Tom Ryan, chairman, president, and chief executive officer of CVS Corp.
The approval ended months of a bitter takeover feud that had the PBM Express Scripts Inc asking Caremark to reject the CVS offer in favor of its hostile bid.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs